Defense Logistics Agency (DLA) Request for Information (RFI): Country of Origin and API Source Disclosure for Generic Pharmaceutical Products

The Defense Logistics Agency (DLA) is seeking information from industry regarding the manufacturing origin and active pharmaceutical ingredient (API) sourcing for generic pharmaceutical products. The agency is evaluating supply chain transparency and potential country-of-origin disclosure requirements for generic pharmaceuticals. Respondents are asked to provide information on the country of origin for their generic pharmaceutical products, including the country where the finished dosage form is manufactured and the country of origin for each API. They are also asked to provide feedback on the feasibility of meeting proposed disclosure and labeling requirements. • The DLA is seeking information on the manufacturing locations of finished dosage forms and the country of origin for each API used in the listed products. • Respondents are asked to provide a product-level table or matrix and supporting documentation, if available. • The DLA encourages respondents to clearly identify any proprietary or business-sensitive information. • The agency is also seeking feedback on the impact of proposed updated label requirements and any operational, regulatory, supply chain, or cost impacts that may result from implementing these requirements.